Unknown

Dataset Information

0

The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.


ABSTRACT: It is unknown if the cardioprotective and renal effects of glucagon-like peptide-1 receptor agonists are consistent across blood pressure (BP) categories in patients with type 2 diabetes and at high risk of cardiovascular events. Using data from the LEADER (9340 patients) and SUSTAIN 6 (3297 patients) trials, we evaluated post hoc the cardiorenal effect of liraglutide and semaglutide on major adverse cardiovascular events (MACE) and nephropathy by baseline BP categories using a Cox proportional hazards model (treatment and subgroup as factors; adjusted for cardiorenal risk factors). Data from the two trials were analysed separately. In the LEADER and SUSTAIN 6 trials, the prevalence of stage 1 hypertension was 30% and 31%, respectively, and of stage 2 hypertension 41% and 43%, respectively. There was no statistical heterogeneity across the BP categories for the effects of liraglutide (P =?.06 for MACE; P =?.14 for nephropathy) or semaglutide (P =?.40 for MACE; P =?.27 for nephropathy) versus placebo. This implies that liraglutide and semaglutide may be beneficial for patients with type 2 diabetes, irrespective of their baseline BP.

SUBMITTER: Leiter LA 

PROVIDER: S-EPMC7496251 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials.

Leiter Lawrence A LA   Bain Stephen C SC   Bhatt Deepak L DL   Buse John B JB   Mazer C David CD   Pratley Richard E RE   Rasmussen Søren S   Ripa Maria Sejersten MS   Vrazic Hrvoje H   Verma Subodh S  

Diabetes, obesity & metabolism 20200603 9


It is unknown if the cardioprotective and renal effects of glucagon-like peptide-1 receptor agonists are consistent across blood pressure (BP) categories in patients with type 2 diabetes and at high risk of cardiovascular events. Using data from the LEADER (9340 patients) and SUSTAIN 6 (3297 patients) trials, we evaluated post hoc the cardiorenal effect of liraglutide and semaglutide on major adverse cardiovascular events (MACE) and nephropathy by baseline BP categories using a Cox proportional  ...[more]

Similar Datasets

| S-EPMC7754406 | biostudies-literature
| S-EPMC8860212 | biostudies-literature
| S-EPMC6619033 | biostudies-literature
| S-EPMC6099440 | biostudies-literature
| S-EPMC6474072 | biostudies-literature
| S-EPMC7065219 | biostudies-literature
| S-EPMC6771774 | biostudies-literature
| S-EPMC6250637 | biostudies-literature
| S-EPMC7594204 | biostudies-literature
| S-EPMC4856174 | biostudies-literature